The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas |
Type de publication | Journal Article |
Year of Publication | 2015 |
Auteurs | Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C |
Journal | JOURNAL OF HEMATOLOGY & ONCOLOGY |
Volume | 8 |
Pagination | 52 |
Date Published | MAY 15 |
Type of Article | Article |
ISSN | 1756-8722 |
Mots-clés | Docetaxel, Gastric cancer, Gastroesophageal cancer, Neoadjuvant, Paclitaxel, Preoperative, Signet ring cell, Taxane |
Résumé | The benefit of preoperative chemotherapy in resectable gastroesophageal adenocarcinomas was not observed in signet ring cell subtype. However, the potential interest of taxane-based preoperative chemotherapy on this subtype is still an unresolved issue. Nineteen patients with localized signet ring cell adenocarcinomas received taxane-based regimens, and 17 patients underwent surgery. Complete resection was achieved in 80 %, and median overall survival was 40.8 months (95 % confidence interval (CI), 20.2-not reached). Even though one patient achieved a complete pathological response, seven patients had an upstaging of their tumors at surgery. The potential benefits of taxane-based chemotherapy seem to be limited to a reduced number of patients. |
DOI | 10.1186/s13045-015-0148-y |